Group 1 - The core point of the article is that KaiNeng Health has appointed its Vice Chairman, Qu Yaming, as the Chairman of YuanNeng Cell Technology Group, which is expected to enhance the company's post-investment management of YuanNeng Group and align with the interests of the company and all shareholders [1] Group 2 - The appointment of Qu Yaming as Chairman was approved by the shareholders' meeting, indicating compliance with relevant laws, regulations, and the company's articles of association [1] - This leadership change is seen as a strategic move to strengthen the company's governance and oversight of its investments in YuanNeng Group [1]

Canature 2024 Environmental, Social and Governance (ESG) Report 開能 anature m to to to to to to to the may to B B B B B B 0 0 100 TO BO BO T ■ ■ TO TO TO T it CD 200 LI 2024 Environmental, Social, and Governance (ESG) Report Content | Content. | | --- | | About This Report. | | Board Of Directors Statement . | | Message From The Chairman. | | 2024 Big Data. | | About Canature . | | Esg Governance . | | Esg Governance Structure | | Stakeholder Engagement . | | MATERIAL ISSUES IDENTIFICATION . | | Green Develo ...

公司副董事长瞿亚明先生同时担任原能集团的董事长符合《公司法》等相 关法律法规及《公司章程》的有关规定，有助于公司加强对原能集团的投后管 理，也符合公司和全体股东利益，不存在损害中小股东利益的情况。 特此公告。 关于自愿披露公司重要对外投资原能细胞科技集团股份有 限公司董事长变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 原能细胞科技集团股份有限公司（以下简称"原能集团"）为开能健康科技 集团股份有限公司（以下简称"开能健康"或"公司"）于2014年7月16日创办 成立，原能集团总部位于上海张江生物医药产业基地的核心区域，主要从事围绕 细胞深低温第三方存储服务、细胞药物研发生产、细胞制剂研发生产、细胞因子 化妆品研发及相关自动化存储设备的研发、生产、销售，致力于解决大健康行业 的痛点和问题，布局了相关的核心企业和核心业务。截止目前，原能集团注册资 本为54,605.10万元，开能健康持有其43.6956%的股权。 公司始终坚持"双能驱动"发展战略，在保证净水主业有序健康快速发展的 基础上，公司不断加大对原能细胞积极探索细胞行业布局的支持，原能集团与开 ...

Group 1 - The company, Kaineng Health Technology Group Co., Ltd., has received approval for the issuance of convertible bonds to unspecified objects, with the registration approval dated June 17, 2023 [2] - The bond issuance was approved by the company's board meeting on October 28, 2022, and the third extraordinary general meeting of shareholders on November 15, 2022 [2] - The convertible bonds will be listed on the Shenzhen Stock Exchange, with a maturity date set for July 19, 2029 [2] Group 2 - The company plans to distribute cash dividends of RMB 0.4 per 10 shares (including tax) to all shareholders, with the record date for this distribution set for May 29, 2025 [3][4] - The conversion price of the convertible bonds will be adjusted from RMB 5.4 per share to RMB 5.36 per share effective from May 30, 2025, due to the cash dividend distribution [3][4] - The adjustment of the conversion price is based on the company's profit distribution plan and follows the guidelines outlined in the prospectus [3][4] Group 3 - The company has established a formula for adjusting the conversion price based on various corporate actions, including cash dividends and stock distributions [4] - The adjustment process will be communicated through announcements on the Shenzhen Stock Exchange and other media as required by regulatory authorities [4][5] - The company will ensure that any changes affecting the rights of convertible bondholders will be handled fairly and transparently [5] Group 4 - The adjustments to the conversion price due to the profit distribution plan do not impact the company's daily operations or debt repayment capabilities [6] - The bond trustee, Changjiang Securities, will continue to monitor the repayment of principal and interest on the convertible bonds and other significant matters affecting bondholder rights [7]

证券代码：300272 证券简称：开能健康 公告编号：2025-038 债券代码：123206 债券简称：开能转债 特此公告。 开能健康科技集团股份有限公司 董 事 会 二〇二五年五月二十九日 1、债券代码：123206；债券简称：开能转债 2、转股起止时间：2024 年 1 月 26 日至 2029 年 7 月 19 日 3、暂停转股时间：2025 年 5 月 22 日至 2025 年 5 月 29 日 4、恢复转股时间：2025 年 5 月 30 日 开能健康科技集团股份有限公司 关于开能转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 开能健康科技集团股份有限公司（以下简称"公司"）因实施2024年年度权益 分派，根据《开能健康科技集团股份有限公司向不特定对象发行可转换公司债券 募集说明书》及相关规定，开能转债自2025年5月22日至2024年年度权益分派股 权登记日（2025年5月29日）暂停转股。具体内容详见公司于2025年5月21日在巨 潮资讯网(www.cninfo.com.cn)披露的《关于实施权益分派期间开 ...

证券简称：开能健康 证券代码：300272 债券简称：开能转债 债券代码：123206 开能健康科技集团股份有限公司 向不特定对象发行可转换公司债券 2025 年度第二次临时受托管理事务报告 债券受托管理人 二零二五年五月 重要声明 本次发行可转债相关事项已经公司 2022 年 10 月 28 日召开的第五届董事 会第二十三次会议以及 2022 年 11 月 15 日召开的 2022 年第三次临时股东大会 通过。 2023 年 4 月 27 日，开能健康科技集团股份有限公司向不特定对象发行可 转换公司债券获得深圳证券交易所上市审核委员会审核通过。 2023 年 7 月 3 日，公司收到中国证监会出具的《关于同意开能健康科技集 团股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可 [2023]1321 号），批文落款日期为 2023 年 6 月 17 日。 二、本期债券的基本情况 1、可转换公司债券简称：开能转债 本报告依据《可转换公司债券管理办法》（以下简称"管理办法"）、《公 司债券受托管理人执业行为准则》《开能健康科技集团股份有限公司向不特定对 象发行可转换公司债券募集说明书》（以下简称"《 ...

| | | 开能健康科技集团股份有限公司 关于使用闲置自有资金进行委托理财赎回的公告 三、备查文件 金融机构业务回单。 特此公告。 近日，公司使用闲置自有资金购买的理财产品进行到期赎回，现将具体情况 公告如下： | 购买 | 受托方 | 产品名称 | 产品类型 | 金额 | 起始 | 赎回 | 是否 到期 | 理财收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | | | | （万元） | 日 | 日 | | 益 | | | | | | | | | 赎回 | （万元） | | | 兴银理财 | 兴银理财稳添利 | 公募风险等 | | 2025 | 2025 | 无固 定期 | 8.34 | | 开能 | 有限责任 | 日盈 40 号 A 固 | 级一级 | | 年 4 | 年 5 | | | | 健康 | 公司 | 收类理财产品 | （低）固定 | 4,000 | 月 15 | 月 22 | | | | | | | 收益类 | | 日 | 日 | 限 | | 一、 本次赎回理财产品的基本情况 公司与上述委托理财的受托方不存在关联 ...

Group 1 - The company, Kaineng Health Technology Group Co., Ltd., has received approval from the China Securities Regulatory Commission to issue 2.5 million convertible bonds, raising a total of 250 million yuan, with a maturity period of six years from July 20, 2023, to July 19, 2029 [1] - The convertible bond, referred to as "Kaineng Convertible Bond," was listed on August 8, 2023 [1] - The adjustment of the conversion price for the convertible bonds will occur under specific circumstances such as stock dividends, capital increases, or cash dividends, following a defined formula [1][2] Group 2 - The conversion price adjustments will be announced on the Shenzhen Stock Exchange and other media, detailing the adjustment date and method [2] - Historical adjustments to the conversion price have occurred due to cash dividend distributions, with the price changing from 5.67 yuan to 5.62 yuan, and subsequently to 5.52 yuan, 5.47 yuan, and finally to 5.4 yuan [2][3][4] - The latest adjustment, effective from May 30, 2025, will reduce the conversion price from 5.4 yuan to 5.36 yuan due to a cash dividend distribution of 0.4 yuan per 10 shares [4]

Summary of Key Points Core Viewpoint - The company has approved a profit distribution plan for the 2024 fiscal year, which includes a cash dividend of RMB 0.4 per 10 shares for all shareholders, totaling approximately RMB 22.6 million [1][2][3]. Group 1: Profit Distribution Plan - The total share capital after accounting for treasury shares is 565,074,561 shares, and the cash dividend will be distributed based on this adjusted total [1][2]. - The cash dividend will be paid to all shareholders without issuing additional shares or capital reserve transfers [1][2]. - The dividend distribution will be executed on May 30, 2025, with the record date set for May 29, 2025 [3]. Group 2: Taxation and Shareholder Eligibility - Different tax rates will apply for individual shareholders based on their holding periods, with no withholding tax for shares held over one year [2][3]. - The distribution will exclude treasury shares, and the company will bear any legal responsibilities for insufficient cash dividends due to reduced share counts during the distribution period [3]. Group 3: Adjustments and Future Implications - The ex-dividend reference price will be adjusted based on the previous closing price minus RMB 0.0391584 [4]. - The conversion price for convertible bonds will be adjusted from RMB 5.40 to RMB 5.36 per share, effective from the ex-dividend date [4].

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-036 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于可转换公司债券转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 增发新股或配股：P1=（P0+A×k）/（1+k）； 特别提示： 1、初始转股价格：5.67 元/股 ； 2、本次调整前转股价格为 5.4 元/股； 3、本次调整后转股价格为：5.36 元/股，生效日：2025 年 5 月 30 日。 一、可转债基本情况 根据中国证券监督管理委员会出具的《关于同意开能健康科技集团股份有限 公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1321号）， 同意开能健康科技集团股份有限公司（以下简称"开能健康"）向不特定对象发 行可转换公司债券250万张（债券简称：开能转债；债券代码：123206），每张 面值为100元，募集资金总额为25,000万元，期限为自发行之日起六年，即自2023 年7月20日至2029年 ...